|
| | Liver | Lung | Kidney | Heart |
|
Species distribution
(% among IFIs) [3] | Candidiasis 78.7%
Aspergillus sp. 7.9%
Crypto sp. 7.1%
Zygomycetes 3.1%
Other molds 0% | Candidiasis 23.9%
Aspergillus sp. 63%
Crypto sp. 2.2%
Zygomycetes 2.2%
Other molds 9.7% | Candidiasis 60.6%
Aspergillus sp. 11.9%
Crypto sp. 19.3%
Zygomycetes 0.9%
Other molds 2.7% | Candidiasis 65%
Aspergillus sp. 25%
Crypto sp. 2.5%
Zygomycetes 2.5%
Other molds 2.5% |
|
| Median time to IA, days [3] | 99.5 | 504 | — | 382 |
|
| Risk factors for IA [50] |
Re-transplantation
Renal failure, particularly hemodialysis transplantation for fulminant hepatic failure
Reoperation | Single lung transplant
Early airway ischemia
CMV infection
Rejection and augmented immunosuppression Pretransplant Aspergillus colonization
Posttransplant Aspergillus colonization within a year of transplant
Acquired hypogammaglobulinemia | Graft failure requiring hemodialysis
High and prolonged duration of corticosteroids | Isolation of Aspergillus species in respiratory tract cultures Reoperation
CMV disease
Posttransplant hemodialysis
Existence of an episode of invasive aspergillosis in the
program 2 months before or after heart transplant |
|
| Site of IMIs | Lung 70.6%
Sinus 17.6%
Skin and soft tissue 35.3% | Lung 100%
Sinus 9.5%
Skin and soft tissue 0% | Lung 85.3%
Sinus 5.6%
Skin and soft tissue 11.1% | Lung 66.7%
Sinus 16.7%
Skin and soft tissue 33.3% |
|
| Chest CT findings for patients with IA | Nodular lesions 0%
Infiltrates/consolidations 73% | Nodular lesions 20%
Infiltrates/consolidations 80% | Nodular lesions 50%
Infiltrates/consolidations 50% | Nodular lesions 67%
Infiltrates/consolidations 33% |
|
